Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes

References

• Benowitz N. L., Nguyen T., Jones R. T., Herning R. I., Bachman J. Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clinical Pharmacology and Therapeutics 1980; 28: 115–120
   PubMed Web of Science ®Google Scholar
• Bertault-peres P., Bonfils C., Fabre G., Just S., Cano J. P., Maurel P. Metabolism of cyclosporin A. II. Implication of the macrolide antibiotic inducible cytochrome P-450 3c from rabbit liver microsomes. Drug Metabolism and Disposition 1987; 15: 391–398
   PubMedGoogle Scholar
• Bornheim L. M. Effect of cannabidiol on drug metabolism. Biochemistry and Physiology of Substance Abuse, R. R. Watson. CRC Press, Boca Raton 1989; vol. 1: 21–35
   Google Scholar
• Bornheim L. M., Borys H. K., Karler R. Effect of cannabidiol on cytochrome P-450 and hexobarbital sleep time. Biochemical Pharmacology 1981; 30: 503–507
   PubMedGoogle Scholar
• Bornheim L. M., Correia M. A. Selective inactivation of mouse liver cytochrome P-450IIIA by cannabidiol. Molecular Pharmacology 1990; 38: 319–326
   PubMed Web of Science ®Google Scholar
• Bornheim L. M., Correia M. A. Purification and characterization of the major hepatic cannabinoid hydroxylase in mouse: a possible member of the cytochrome P-450IIC subfamily. Molecular Pharmacology 1991; 40: 228–234
   PubMedGoogle Scholar
• Bornheim L. M., Everhart E. T., Li J., Correia M. A. Characterization of cannabidiol-mediated cytochrome P450 inactivation. Biochemical Pharmacology 1993; 45: 1323–1331
   PubMed Web of Science ®Google Scholar
• Bornheim L. M., Lasker J. M., Raucy J. L. Human hepatic microsomal metabolism of δ1-tetrahydrocannabidiol. Drug Metabolism and Disposition 1992; 20: 241–246
   PubMed Web of Science ®Google Scholar
• Combalbert J., Fabre I., Dalet I., Derancourt J., Cano J. P., Maurel. Metabolism of cyclosporin A. IV. Purification and identification of rifampin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P-450 IIIA gene family. Drug Metabolism and Disposition 1989; 17: 197–207
   PubMed Web of Science ®Google Scholar
• Fairbairn J. W., Liebman J. A. The cannabinoid content of Cannabis sativa L. grown in England. Journal of Pharmacy and Pharmacology 1973; 26: 413–419
   Google Scholar
• Fetterman P. S., Keith E. S., Waller C. W., Guerrero O., Doorenbos N. J., Quimby M. W. Mississippi-grown Cannabis sativa L.: preliminary observation on chemical definition of phenotype and variation in tetrahydrocannabinol content versus age, sex, and plant part. Journal of Pharmaceutical Sciences 1971; 60: 1246–1249
   PubMed Web of Science ®Google Scholar
• Kronbach T., Fischer V., Meyer U. A. Cyclosporine metabolism in human liver: identification of a cytochrome P450 III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clinical Pharmacology and Therapeutics 1988; 43: 630–635
   PubMed Web of Science ®Google Scholar
• Lowry O. H., Rosenbrough N. J., Farr A. L., Randall R. J. Protein measurement with the folin phenol reagent. Journal of Biological Chemistry 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Mayer G., Loosli H. R., Schreier E., Keller B. Disposition of cyclosporine in several animal species and man. I. Structural elucidation of its metabolites. Drug Metabolism and Disposition 1984; 12: 120–127
   PubMedGoogle Scholar
• Mayer R. D., Berman S., Cockett A. T. K., Maines M. D. Differential effects of cyclosporin on hepatic renal heme, cytochrome P-450 and drug metabolism—possible role in nephrotoxicity of the drug. Biochemical Pharmacology 1989; 38: 1001–1007
   PubMed Web of Science ®Google Scholar
• Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes II. Solubilization, purification, and properties. Journal of Biological Chemistry 1964; 239: 2370–2378
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T., Correia M. A., Rettie A. E., Swinney D. C., Thomas P. E., Benet L. Z. Cyclosporine metabolism by rat liver microsomes—evidence for involvement of enzyme(s) other than cytochromes P-450 3A. Drug Metabolism and Disposition 1993; 21: 730–737
   PubMed Web of Science ®Google Scholar
• Pichard L., Fabre L., Fabre I., Domergue J., Aubert B. S., Mourad G., Maurel P. Cyclosporine A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metabolism and Disposition 1990; 18: 595–606
   PubMed Web of Science ®Google Scholar
• Sheets J. J., Mason J. I. Ketoconazole: a potent inhibitor of cytochrome P-450-dependent drug metabolism in rat liver. Drug Metabolism and Disposition 1984; 12: 603–607
   PubMed Web of Science ®Google Scholar
• Siemens A. J., Kalant H., Khanna J. M., Marshman J., Ho G. Effect of cannabis on pentobarbital-induced sleeping time and pentobarbital metabolism in the rat. Biochemical Pharmacology 1974; 23: 477–488
   PubMedGoogle Scholar
• Van Der Hoeven T. A., Coon M. J. Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. Journal of Biological Chemistry 1974; 249: 6302–6310
   PubMed Web of Science ®Google Scholar
• Watanabe K., Arai M., Narimatsu S., Yamamoto I., Yoshimura H. Self-catalyzed inactivation of cytochrome P-450 during microsomal metabolism of cannabidiol. Biochemical Pharmacology 1987; 36: 3371–3377
   PubMed Web of Science ®Google Scholar